Peptide Blend Calculator
Target one component and see what the same draw delivers for all the others.
Why a blend has one dose, not two
A blend is not two drugs that happen to share a box. It is one solution containing two or more peptides, and once the water goes in there is no operation you can perform on that vial that changes their proportions. A syringe draws a volume. Every component present at some concentration comes along in that volume, at its own concentration, whether you wanted it or not.
That has three consequences worth stating plainly, because most blend pages skip all three:
- You cannot titrate one component. Halving the draw halves both. If your reason for reaching for a blend was to adjust one of them, a blend is the wrong container for it.
- Water does not help. Diluting further changes both concentrations by the same factor and leaves the ratio untouched. What it does change is where the draw lands on the barrel, which is worth doing when a blend puts your target at two or three units.
- The ratio is the seller’s choice, not a standard. Blend names like KLOW are product names. There is no monograph behind them and no approved product, so the only authority on what is in your vial is the label on your vial.
The calculator above reflects that: you enter each component’s milligrams, aim at one of them, and it shows the volume, the syringe units, and what every other component delivers at that same volume.
What a blend label should tell you, and usually does not
The arithmetic on this page is only as good as the numbers you feed it, and blend labels are the weakest input on the site. Four things have to be on the label for a draw to be calculable at all:
- The mass of each component separately, not a combined total. “10 mg blend” is ambiguous by a factor of two: it usually means 5 mg of each in a two-component vial, and sometimes means 10 mg of each. Nothing standardises it.
- Which components are present, by name. Product names like KLOW are seller inventions with no monograph behind them, so the name alone does not fix the contents — two vials with the same name can hold different things.
- The unit for each. Blends frequently mix scales, with one component in milligrams and another in micrograms. A number without its unit is a thousand-fold ambiguity.
- Nothing about a dose. Where a blend label carries a suggested dose or a “protocol”, that figure has a vendor behind it rather than a study or a regulator, and none of the components in any blend here has an approved human dose in any country.
If your label gives only a total, you cannot recover the split, and no calculator can do it for you. That is not a limitation of this tool — it is missing information about the physical object, and the honest response is to treat the contents of the draw as unknown.
The evidence problem is separate from the arithmetic problem
Worth separating, because they get run together. The arithmetic above is exact: given the masses and the water volume, what a draw contains is a calculation with one answer.
The evidence is a different matter. No published study has tested any of these combinations as a combination. What exists is thin single-agent literature — one 2006 human study for CJC-1295 with DAC, one 1999 single-dose intravenous pharmacokinetic study for ipamorelin, and review-level literature for BPC-157 and TB-500 with no approved human dose behind any of it. A blend is therefore two or more unknowns sold as one product, with the additional property that you cannot separate them after the fact.
Blends with their own page
Each one carries the regulatory status of every component, the evidence base, and the same calculator preloaded with the ratios that vial is usually sold in.
- BPC-157 + TB-500 blendBPC-157 + TB-500
- CJC-1295 + Ipamorelin blendCJC-1295 + Ipamorelin
- KLOW blendGHK-Cu + BPC-157 + TB-500 + KPV
- GLOW peptide blendGHK-Cu + BPC-157 + TB-500
- Tesamorelin + Ipamorelin blendTesamorelin + Ipamorelin
Holding a single-peptide vial instead? Every peptide calculator is here, and this guide explains what any of these tools can and cannot know.
Common questions
Sources used on this page
Every number on this page comes from one of the documents below. Where no reliable source exists, the page says so instead of filling the gap.
- RegulatorFDA· 2026-05-14Bulk Drug Substances Nominated for Use in Compounding Under Section 503A
- RegulatorFDACertain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks
- RegulatorFDA· 2026-07July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorFDA· 2024-10October 29, 2024 Meeting of the Pharmacy Compounding Advisory Committee
- RegulatorFDA· 2024-12-04PCAC briefing document — substance descriptions and 503A statutory conditions
- RegulatorFDA· 2026-08-24Warning Letter — Peak Performance Peptides (research-use-only labelling does not exempt an unapproved new drug)
- RegulatorFDACompounding Risk Alerts
- Published studyJournal of Clinical Endocrinology & Metabolism· 2006Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting GHRH analog
- Published studyPharmaceutical Research· 1999Gobburu JVS et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in healthy men
- Published studyPubMed CentralSikirić P et al. Stable gastric pentadecapeptide BPC 157 — a review of the rodent literature
- Published studyPubMed CentralThymosin beta-4 (RGN-259) phase 3 in neurotrophic keratopathy
- GuidelineInternational Organization for Standardization· 2016-03ISO 8537:2016 — Sterile single-use syringes, with or without needle, for insulin (scope and requirements; full text not public)